PDGFRβ AND C-ABL ACTIVATION ASSOCIATE WITH OUTCOME AND RESPONSE TO SORAFENIB IN DESMOID PATIENTS TREATED ON THE PHASE III ALLIANCE A091105 TRIAL
HomeAbout DTRFNews & Updates
PDGFRβ AND C-ABL ACTIVATION ASSOCIATE WITH OUTCOME AND RESPONSE TO SORAFENIB IN DESMOID PATIENTS TREATED ON THE PHASE III ALLIANCE A091105 TRIAL
Stay Up to Date as We Uncover More About Desmoid Tumors
